Short-term Outcomes of COVID-19 and Risk Factors for Progression

Eur Respir J. 2020 May 27;55(5):2000990. doi: 10.1183/13993003.00990-2020. Print 2020 May.

Abstract

With a median (IQR) follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe and 66.7% critical COVID-19. Neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male sex and comorbidity were associated with progression. https://bit.ly/3crsJr0

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Betacoronavirus
  • China
  • Comorbidity
  • Coronavirus Infections
  • Humans
  • Pandemics
  • Pneumonia, Viral
  • Risk Factors

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2